In 2018, Yao et al. [130] reported yet another novel inhibitor, 7594-0035, specifically targeting Myc for the potential treatment of relapsed/refractory multiple myeloma (MM), in which frontline therapy-resistance has been associated with Myc [131,132]. Here, MYC is linked to plasma cell myeloma.